Ben Shamsian
Investor Relations, Litham Partners
Replay available
Biofrontera Inc. (NASDAQ: BFRI) Q4 2025 earnings conference call, held 2026-03-19. Replay captured from the company's public earnings webcast.

Investor Relations, Litham Partners
CEO, Chairman, and Founder of BioFrontera Inc.
Chief Commercial Officer
Chief Financial Officer
Analyst, The Benchmark Company
Welcome to the Biofrontera Inc. Fourth Quarter and Full Year twenty twenty five Financial Results and Business Update Conference Call. At this time, all participants are in listen only mode. After today's prepared remarks, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Ben Shamsian with Lithium Partners Investor Relations. Please go ahead. Thank you. Good morning and welcome to Biofrontera's fourth quarter and full year twenty twenty five financial results and business update conference call. Please note that certain information discussed during today's call by management is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that Biofrontera's management will be making forward looking statements and that actual results may differ materially from those stated or implied by these forward looking statements due to risks and uncertainties associated with the company's business. All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in Biofrontera's press releases and SEC filings, including the company's annual report on Form 10 ks and the year ended twelvethirty onetwenty twenty five. Also, this conference call contains time sensitive information that is accurate only as of the date of the live broadcast. Biofrontera undertakes no obligation to revise or update any forward looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, there will be references to certain non GAAP financial measures. Biofrontera believes these measures provide useful information for investors, yet should not be consider...